Context Therapeutics (CNTX) Operating Expenses (2020 - 2026)
Context Therapeutics (CNTX) posted Operating Expenses of $1.9 million for Q1 2026, down 43.18% sequentially from $3.4 million in Q4 2025, and up 79.57% YoY from $1.1 million in Q1 2025.
Context Therapeutics (CNTX) Operating Expenses (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Operating Expenses for 7 years, with the latest figure at $1.9 million in Q1 2026.
- Quarterly Operating Expenses rose 79.57% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (up 34.58% YoY) and the FY2025 annual result came in at $6.8 million, up 40.49% from the prior year.
- Operating Expenses declined to $1.9 million in Q1 2026 per CNTX's latest filing, from $3.4 million in the prior quarter.
- Over five years, Operating Expenses peaked at $11.0 million in Q3 2024 and troughed at -$6.1 million in Q4 2024.
- A 5-year average of $3.6 million and a median of $3.5 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2024: Operating Expenses surged 309.72% in 2022, then sank 188.63% in 2024.
- Over 5 years, Operating Expenses stood at $3.9 million in 2022, then jumped by 78.58% to $6.9 million in 2023, then tumbled by 188.63% to -$6.1 million in 2024, then surged by 154.56% to $3.4 million in 2025, then tumbled by 43.18% to $1.9 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $1.9 million, $3.4 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Context Therapeutics | 49.23 Mn | 49.23 Mn | - | 7.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.53 Mn |
| Mar 31, 2026 | 1.90 Mn |
| Dec 31, 2025 | 3.35 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.49 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | -6.15 Mn |
| Sep 30, 2024 | 11.02 Mn |
| Dec 31, 2023 | 6.93 Mn |
| Sep 30, 2023 | 6.18 Mn |
| Jun 30, 2023 | 5.29 Mn |
| Mar 31, 2023 | 6.67 Mn |
| Dec 31, 2022 | 3.88 Mn |
| Sep 30, 2022 | 4.05 Mn |
| Jun 30, 2022 | 3.51 Mn |
| Mar 31, 2022 | 3.44 Mn |
| Dec 31, 2021 | 3.09 Mn |
| Sep 30, 2021 | 1.57 Mn |
| Jun 30, 2021 | 1.94 Mn |
| Mar 31, 2021 | 840,318.00 |